Methocarbamol, a medication categorized as a skeletal muscle relaxant, plays a crucial role in managing acute musculoskeletal pain. This comprehensive guide delves into the essential aspects of methocarbamol, exploring its primary uses, how it works, and important safety considerations. Understanding these details empowers healthcare professionals to develop effective treatment plans and ensure optimal patient care. By focusing on its pharmacology, this article aims to equip healthcare providers with the knowledge to precisely address patient needs, highlighting the collaborative effort of the interprofessional healthcare team in successful methocarbamol therapy for musculoskeletal pain relief.
This resource provides healthcare professionals with valuable insights and practical tools for utilizing methocarbamol effectively in patient care. With a strong emphasis on evidence-based medicine, this discussion enhances the understanding needed for informed decision-making, appropriate dosage adjustments, and minimizing potential adverse reactions. Ultimately, this educational content is designed to improve patient outcomes in various conditions where methocarbamol is indicated for alleviating musculoskeletal pain and related symptoms.
Objectives:
- Clearly identify the approved and off-label uses of methocarbamol in treating musculoskeletal pain.
- Recognize patient populations who are at increased risk of experiencing adverse effects from methocarbamol.
- Compare and contrast different therapeutic approaches using anti-spastic and anti-spasmodic skeletal muscle relaxants.
- Foster effective communication and collaboration within interprofessional healthcare teams to optimize treatment outcomes for patients benefiting from methocarbamol therapy.
Access free multiple choice questions on this topic.
Indications for Methocarbamol Use
Methocarbamol is officially recognized as a centrally-acting skeletal muscle relaxant (SMR). It has received approval from the United States Food and Drug Administration (FDA) for the management of acute musculoskeletal pain conditions. Dating back to its initial FDA approval in 1957, methocarbamol has been a trusted medication for alleviating muscle spasms.[1] Its therapeutic effectiveness is well-documented within the broader category of muscle relaxants.[2] Specifically, methocarbamol is classified as an anti-spasmodic agent. This means it is designed to treat involuntary skeletal muscle spasms, distinguishing it from anti-spastic medications such as dantrolene and baclofen. Anti-spastic agents are targeted towards spasticity that arises from upper motor neuron disorders. Other commonly prescribed anti-spasmodic agents include carisoprodol and cyclobenzaprine. Notably, medications like diazepam and tizanidine possess both anti-spastic and anti-spasmodic properties.[3] While these different classes of medications work through varying mechanisms, this article will primarily focus on methocarbamol.
Methocarbamol’s journey began with its discovery in the early 1950s, culminating in its regulatory approval in 1957.[1] A significant early study in 1958 by O’Doherty and Shields highlighted methocarbamol’s effectiveness in treating muscle spasms in patients with pyramidal spine lesions, such as herniated intervertebral discs.[4] Around the same time, Forsyth’s research further supported these findings through a case series involving 100 patients with various orthopedic conditions, including post-operative muscle spasm and both acute and chronic disc herniation. In Forsyth’s study, a vast majority of patients, all but six, reported “moderate” to “pronounced” relief from subjective pain and spasms. Importantly, significant adverse effects were minimal, with only a small fraction of patients reporting “minor” side effects like dizziness and nausea.[5] Despite its widespread use today, it’s important to acknowledge that there’s a limited number of robust, high-quality studies, and a lack of meta-analyses comparing methocarbamol against placebo or other alternatives for muscle spasms.[6] This highlights an area for potential future research to further solidify its evidence base.
FDA-Approved Uses of Methocarbamol
Currently, methocarbamol’s primary clinical application is as an adjunctive treatment for acute musculoskeletal pain. Clinical guidelines from organizations like the American College of Physicians emphasize prioritizing nonpharmacologic approaches for acute or subacute low back pain. However, when pharmacological intervention is deemed necessary, the guidelines suggest nonsteroidal anti-inflammatory drugs (NSAIDs) and skeletal muscle relaxants, including methocarbamol, as viable options.[7]
Off-Label Applications of Methocarbamol
Beyond its FDA-approved uses, methocarbamol has been explored for various off-label applications in managing painful conditions. These include acute and chronic non-specific low-back pain, inflammatory arthritis, fibromyalgia, rib fractures, myofascial pain, abdominal muscle cramps in patients with cirrhosis, and in perioperative care for hip and knee replacements.[8, 9, 10, 11, 12] It’s worth noting that for tetanus treatment, benzodiazepines have largely replaced methocarbamol.[13] Methocarbamol is not considered effective for conditions like contracture, rigidity, or spasticity believed to originate from upper motor neuron injuries. Interestingly, a recent case report has suggested a potential role for methocarbamol in managing tizanidine withdrawal.[14]
Methocarbamol’s Mechanism of Action
The precise mechanism by which methocarbamol exerts its muscle relaxant effects is not fully understood. One prevailing theory suggests that involuntary muscle spasms might initially serve as a protective reflex, preventing movements that could lead to further injury. However, in some instances, these muscle spasms themselves can become a source of significant pain and disability. This concept, known as the “pain-spasm-pain cycle,” remains a subject of debate, lacking definitive confirmation in rigorous clinical and electrophysiologic studies.[9] The development of methocarbamol, along with other muscle relaxants, was rooted in animal studies that demonstrated a reduction in muscle tone without causing a generalized depression of motor activity.[15]
Theoretically, the pain relief offered by skeletal muscle relaxants (SMRs) like methocarbamol is thought to stem from overall central nervous system (CNS) depression. Another proposed mechanism involves the anticholinergic inhibition of the midbrain reticular activating system. This inhibition leads to a decrease in polysynaptic reflexes and a subsequent reduction in muscle tone. This action is also described as an indirect inhibition of the interneuronal junction in the spinal cord. It’s important to note that methocarbamol does not directly impact skeletal muscle contractility, motor nerve fibers, or the motor end plate.[4]
Pharmacokinetics of Methocarbamol
Understanding how methocarbamol is processed in the body is crucial for effective and safe use. Here’s a breakdown of its pharmacokinetics:
Absorption: Oral methocarbamol begins to take effect within approximately 30 minutes of ingestion. It is efficiently absorbed from the gastrointestinal tract, reaching peak plasma concentrations around 2 hours post-administration.[16]
Distribution: Methocarbamol exhibits moderate binding to plasma proteins, with binding typically ranging between 46% and 50%.
Metabolism: The drug undergoes metabolism primarily through dealkylation and hydroxylation pathways. These processes may be followed by conjugation.
Elimination: In healthy individuals, methocarbamol demonstrates plasma clearance rates ranging from 0.20 to 0.80 L/h/kg. Its average plasma elimination half-life is between 1 and 2 hours. Methocarbamol is mainly eliminated as inactive metabolites in the urine. Based on these pharmacokinetic properties, it is typically dosed every 6 hours in clinical practice. Studies in hemodialysis patients have shown that methocarbamol’s elimination time remains unchanged compared to individuals with normal renal function, although renal clearance is reduced.[17] Similarly, clearance is reduced in patients with cirrhosis; however, specific dosage adjustments are generally not recommended. One study indicated that a dosage of 500 mg twice daily was well-tolerated in patients with cirrhosis.[12]
Administration Guidelines for Methocarbamol
Available Dosage Forms and Strengths
Methocarbamol is most commonly administered orally. It is commercially available in tablet form in strengths of 500 mg and 750 mg. For situations like the postoperative setting, intravenous (IV) and intramuscular (IM) formulations are also available for use.
Adult Dosage Recommendations
The typical daily oral dosage of methocarbamol ranges from 4 to 6 grams, divided into doses administered every 6 hours. While the maximum recommended daily dose is 6 grams, doses up to 8 grams per day have been used in some cases. However, in routine clinical practice, lower doses are frequently employed. For instance, a retrospective study observed that the typical dose for hospitalized patients was 500 mg orally every 8 hours.[10] For IV and IM administration, which are common in postoperative care, a dose of 1 gram can be injected every 8 hours. It’s important to note that the daily dosage should not exceed 3 grams, and use should generally be limited to a maximum of 3 consecutive days.[18, 19]
Dosage Adjustments for Specific Patient Populations
Renal Impairment: The major metabolites of methocarbamol, as well as small amounts of the unchanged drug, are excreted in the urine. Due to the presence of polyethylene glycol excipient, the intravenous formulation of methocarbamol is contraindicated in patients with renal impairment. Oral methocarbamol should be used with caution in patients with mild to moderate renal impairment. Extra caution is advised when administering methocarbamol to patients undergoing dialysis.[17]
Hepatic Impairment: Methocarbamol is metabolized in the liver through dealkylation, hydroxylation, and conjugation. However, current manufacturer guidelines do not provide specific dosage recommendations for patients with hepatic impairment.
Pregnancy Considerations: Methocarbamol is classified as a pregnancy category C medication. Case reports have suggested potential associations between methocarbamol exposure during pregnancy and fetal and congenital abnormalities. Therefore, it is generally advised to avoid methocarbamol use in women who are pregnant or may become pregnant, particularly during the early stages of pregnancy, unless the potential benefits clearly outweigh the risks.[20]
Breastfeeding Considerations: There is a lack of research specifically evaluating methocarbamol use in breastfeeding women. The manufacturer advises caution when considering methocarbamol for nursing mothers. Animal studies indicate that methocarbamol can cross the placental barrier and is excreted in breast milk. Consequently, its use is generally discouraged in women who are breastfeeding or may become pregnant.
Pediatric Patients: The safety and effectiveness of methocarbamol in patients under the age of 16 have not been definitively established.
Older Patients: Skeletal muscle relaxants, including methocarbamol, are included in the Beers Criteria as medications that should generally be avoided in adults 65 years and older. This recommendation is based on associations with a small but statistically significant increased risk of injury in older adults. This “injury” risk is primarily derived from retrospective case-control studies analyzing patients presenting to urgent care, emergency rooms, and hospitals. The injuries of concern include falls, non-vertebral fractures, soft-tissue injuries, and other cognitive or psychomotor disruptions. The estimated absolute risk increase from methocarbamol based on available data is approximately 0.2%. All SMRs, including methocarbamol, possess anticholinergic properties which can contribute to sedation, falls, confusion, and polypharmacy in older adults.[21, 22]
Adverse Effects of Methocarbamol
Serious adverse effects listed in the methocarbamol package insert include seizures, leukopenia, and cholestatic jaundice. However, according to LiverTox, a resource from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), methocarbamol has not been definitively linked to liver or kidney injury.[1] Drug monographs report instances of seizures in patients with a history of epilepsy following IV administration, as well as cases of polysubstance toxicity. Product labeling indicates that neurological adverse reactions are more common, with sedation being the most frequently reported, followed by dizziness and headache. Other reported neurological side effects include confusion, amnesia, falls, syncope, and diplopia. Gastrointestinal adverse effects may include dyspepsia, nausea, vomiting, metallic taste, and cholestatic jaundice. IV administration of methocarbamol has been associated with thrombophlebitis and injection site pain, potentially related to extravasation of the hypertonic solution. Patients should be informed that methocarbamol can cause urine discoloration, although this is considered clinically insignificant.[23]
Drug-Drug Interactions and Abuse Potential
Several studies have investigated the abuse potential of methocarbamol. Animal studies have indicated a low abuse potential compared to substances like barbiturates and benzodiazepines.[24] However, some human studies have reported potential for abuse.[25, 26] Despite these concerns, a recent review of German pharmacovigilance data did not find evidence of abuse potential for methocarbamol. The authors of this review did acknowledge that under-reporting of adverse effects is a limitation, so the concern for potential abuse should still be considered. It is prudent to exercise caution when prescribing methocarbamol to patients who are also taking other central nervous system depressants, such as opioids and benzodiazepines, or who have a history of substance use disorders.[27]
Contraindications for Methocarbamol Use
According to the FDA, methocarbamol is contraindicated in individuals with a known hypersensitivity to methocarbamol itself or any of its excipients. Furthermore, IV methocarbamol is contraindicated in patients with renal impairment due to the polyethylene glycol excipient, which carries a risk of metabolic acidosis, renal injury, and hyperosmolarity.[28] As previously mentioned, while animal studies suggest a low abuse potential, human studies and pharmacovigilance data indicate a need for caution regarding potential abuse, particularly in individuals with substance use disorders or those taking other CNS depressants. Methocarbamol should be used cautiously in combination with other central nervous system (CNS) depressants, including benzodiazepines, opioids, and in patients with known substance use disorders.
Warnings and Precautions
Myasthenia Gravis: Methocarbamol is contraindicated in patients with myasthenia gravis who are also taking acetylcholinesterase inhibitors. This contraindication is based on a case report of exacerbated muscle weakness and fatigue potentially linked to methocarbamol’s anticholinergic effects.[29]
Beers Criteria: As noted earlier, methocarbamol is listed in the Beers Criteria and should be avoided in older adults due to the increased risk of falls, fractures, soft-tissue injuries, and cognitive or psychomotor impairment.[21]
Drug-Laboratory Interference: Methocarbamol can interfere with urine screening tests for vanillyl mandelic acid (VMA) and 5-hydroxy indole acetic acid (5-HIAA).[30] This potential interference should be considered when interpreting results of these tests.
Monitoring Methocarbamol Therapy
Recommended monitoring during methocarbamol therapy involves assessing the patient’s clinical response to the medication and monitoring for the emergence of any adverse effects. Routine blood chemistry checks or therapeutic drug monitoring are not typically required. Patient populations at higher risk for toxicity include those with cirrhosis, individuals using multiple CNS depressants, patients with renal impairment, those with substance use disorders, and older adults.[22]
Methocarbamol Toxicity and Overdose Management
Signs and Symptoms of Overdose
Isolated methocarbamol overdose is relatively uncommon and generally not life-threatening unless multiple drugs are involved.[31] Based on limited data, symptoms of toxicity may include nausea, sedation, seizures, coma, and in rare cases, death.
Management of Overdose
There is no specific antidote for methocarbamol overdose. Treatment is primarily supportive, focusing on managing symptoms and maintaining vital functions. A retrospective study analyzing data from the National Poison Data System from 2010 to 2020 examined skeletal muscle relaxant exposures in pediatric and adolescent populations. This study identified 2605 cases of single-agent exposures to carisoprodol, meprobamate, methocarbamol, or metaxalone in patients aged 6 to 19. The findings indicated that the majority of these cases (75.74%) were intentional exposures, with suicide attempts accounting for over half of these. Common clinical effects observed included drowsiness, tachycardia, vomiting, and slurred speech. Most exposures (81.04%) required referral or management at healthcare facilities, with intravenous fluids and activated charcoal being common interventions. This study highlights the importance of understanding skeletal muscle relaxant toxicity, particularly in adolescents, to guide effective management strategies.[32]
Enhancing Healthcare Team Outcomes in Methocarbamol Therapy
Skeletal muscle relaxants like methocarbamol are frequently prescribed for non-specific musculoskeletal pain. In 2004, it was estimated that approximately 2 million adults in the United States were using a muscle relaxant, with low back pain being the most common reason.[33] Globally, low back pain was a leading cause of years lived with disability in 2016.[34] Often, a specific nociceptive cause for low back pain is difficult to pinpoint. In such cases, symptoms are likely multifactorial, involving biomechanical pain generators, central and peripheral nociceptive processing, medical comorbidities, and psychosocial factors.[35] When a specific cause cannot be identified, a biopsychosocial approach to management is recommended, acknowledging the complexity of factors contributing to low back pain. Initial treatment recommendations often prioritize non-pharmacologic strategies, including patient education, maintaining activity levels, and using heat or ice therapy.[36] Pharmacologic treatments can be considered for persistent symptoms but should be integrated into a comprehensive, multimodal treatment plan that may also include psychological and biomechanically oriented therapies.
Despite the high volume of methocarbamol prescriptions in the United States (over 3 million annually), robust, high-quality evidence demonstrating its clinical efficacy remains limited.[1] Current evidence suggests methocarbamol is more effective than placebo for acute musculoskeletal pain and comparable in efficacy to other muscle relaxants. However, these conclusions are largely based on older, smaller case series and small randomized clinical trials (RCTs).[37] There is conflicting evidence regarding whether methocarbamol offers any additional benefit or is superior to NSAIDs for musculoskeletal pain. A randomized controlled trial in 2018 by Friedman et al. found that adding methocarbamol to naproxen did not improve outcomes at 1 week, although the study was relatively small. This research group also reported similar findings when methocarbamol was added to oxycodone-acetaminophen, cyclobenzaprine, corticosteroids, and diazepam.[38]
Conversely, a retrospective cohort study published in 2024 investigated injury risks associated with combining SMRs with commonly prescribed opioids in a US Medicaid population. The study revealed variations in injury rates depending on the specific SMR-opioid combinations and the sequence of initiation. Notably, methocarbamol consistently showed lower injury rates compared to other SMRs like carisoprodol and tizanidine when used concurrently with oxycodone or tramadol. These results offer valuable insights for optimizing pain management strategies and underscore the need for further research to validate these findings and guide evidence-based clinical practice.[39]
Clinicians should exercise vigilance when prescribing methocarbamol, particularly to older patients and those at risk of polypharmacy. It’s crucial to remember that strong evidence supporting methocarbamol’s superiority over NSAIDs for acute musculoskeletal pain is lacking. Nurses and pharmacists play a vital role in ensuring methocarbamol is used judiciously in select patients as part of a multimodal treatment approach, with careful monitoring of efficacy, adverse effects, and potential polypharmacy issues. Furthermore, there is a clear need for more extensive randomized controlled trials to better inform clinical decision-making for a medication that is widely used but lacks a strong evidence base. Effective interprofessional collaboration and open communication among physicians, nurse practitioners, physician assistants, nurses, and pharmacists are essential to optimize patient outcomes related to methocarbamol therapy.
Review Questions
(The review questions section from the original article is omitted as per instructions to only include title and content)
References
1.LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jan 30, 2017. Methocarbamol. [PMC free article: PMC547852] [PubMed: 31643609]
2.van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM., Cochrane Back Review Group. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the cochrane collaboration. Spine (Phila Pa 1976). 2003 Sep 01;28(17):1978-92. [PubMed: 12973146]
3.See S, Ginzburg R. Skeletal muscle relaxants. Pharmacotherapy. 2008 Feb;28(2):207-13. [PubMed: 18225966]
4.O’DOHERTY DS, SHIELDS CD. Methocarbamol; new agent in treatment of neurological and neuromuscular diseases. J Am Med Assoc. 1958 May 10;167(2):160-3. [PubMed: 13538683]
5.FORSYTH HF. Methocarbamol (robaxin) in orthopedic conditions; preliminary report of one hundred cases. J Am Med Assoc. 1958 May 10;167(2):163-8. [PubMed: 13538684]
6.See S, Ginzburg R. Choosing a skeletal muscle relaxant. Am Fam Physician. 2008 Aug 01;78(3):365-70. [PubMed: 18711953]
7.Qaseem A, Wilt TJ, McLean RM, Forciea MA, Clinical Guidelines Committee of the American College of Physicians. Denberg TD, Barry MJ, Boyd C, Chow RD, Fitterman N, Harris RP, Humphrey LL, Vijan S. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Apr 04;166(7):514-530. [PubMed: 28192789]
8.Richards BL, Whittle SL, van der Heijde DM, Buchbinder R. The efficacy and safety of muscle relaxants in inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl. 2012 Sep;90:34-9. [PubMed: 22942327]
9.Beebe FA, Barkin RL, Barkin S. A clinical and pharmacologic review of skeletal muscle relaxants for musculoskeletal conditions. Am J Ther. 2005 Mar-Apr;12(2):151-71. [PubMed: 15767833]
10.Patanwala AE, Aljuhani O, Kopp BJ, Erstad BL. Methocarbamol use is associated with decreased hospital length of stay in trauma patients with closed rib fractures. Am J Surg. 2017 Oct;214(4):738-742. [PubMed: 28088301]
11.Looke TD, Kluth CT. Effect of preoperative intravenous methocarbamol and intravenous acetaminophen on opioid use after primary total hip and knee replacement. Orthopedics. 2013 Feb;36(2 Suppl):25-32. [PubMed: 23379573]
12.Abd-Elsalam S, Arafa M, Elkadeem M, Elfert A, Soliman S, Elkhalawany W, Badawi R. Randomized-controlled trial of methocarbamol as a novel treatment for muscle cramps in cirrhotic patients. Eur J Gastroenterol Hepatol. 2019 Apr;31(4):499-502. [PubMed: 30444744]
13.UTTERBACK RA, TENNEY PH. METHOCARBAMOL IN THE THERAPY OF TETANUS. Arch Neurol. 1963 Nov;9:555-60. [PubMed: 14057687]
14.Escobar Gil T, McGeorge KJ, Jones AJ. A Case of Tizanidine Withdrawal and Road to Recovery. Cureus. 2024 Feb;16(2):e53444. [PMC free article: PMC10909376] [PubMed: 38435197]
15.TRUITT EB, PATTERSON RB. Comparative hemolytic activity of mephenesin, guaiacol glycerol ether and methocarbamol in vitro and in vivo. Proc Soc Exp Biol Med. 1957 Jul;95(3):422-4. [PubMed: 13453457]
16.Elenbaas JK. Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm. 1980 Oct;37(10):1313-23. [PubMed: 6999895]
17.Sica DA, Comstock TJ, Davis J, Manning L, Powell R, Melikian A, Wright G. Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals. Eur J Clin Pharmacol. 1990;39(2):193-4. [PubMed: 2253675]
18.Dent RW, Ervin DK. Relief of acute musculoskeletal symptoms with intravenous methocarbamol (robaxin injectable): a placebo-controlled study. Curr Ther Res Clin Exp. 1976 Nov;20(5):661-5. [PubMed: 825351]
19.LEVENTEN EO, VACCARINO FP. Intravenous methocarbamol in 100 orthopedic patients. Curr Ther Res Clin Exp. 1960 Oct;2:497-500. [PubMed: 13761355]
20.Hall JG, Reed SD. Teratogens associated with congenital contractures in humans and in animals. Teratology. 1982 Apr;25(2):173-91. [PubMed: 7101197]
21.Spence MM, Shin PJ, Lee EA, Gibbs NE. Risk of injury associated with skeletal muscle relaxant use in older adults. Ann Pharmacother. 2013 Jul-Aug;47(7-8):993-8. [PubMed: 23821610]
22.By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052-2081. [PubMed: 37139824]
23.Viswanathan S. Urine bag as a modern day matula. ISRN Nephrol. 2013;2013:215690. [PMC free article: PMC4045424] [PubMed: 24959539]
24.Sannerud CA, Ator NA, Griffiths RR. Methocarbamol: evaluation of reinforcing and discriminative stimulus effects. Behav Pharmacol. 1991 Apr;2(2):143-150. [PubMed: 11224058]
25.Gahr M, Freudenmann RW, Eller J, Schönfeldt-Lecuona C. Abuse liability of centrally acting non-opioid analgesics and muscle relaxants–a brief update based on a comparison of pharmacovigilance data and evidence from the literature. Int J Neuropsychopharmacol. 2014 Jun;17(6):957-9. [PubMed: 24552880]
26.Preston KL, Wolf B, Guarino JJ, Griffiths RR. Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability. J Pharmacol Exp Ther. 1992 Aug;262(2):707-20. [PubMed: 1501118]
27.Dawwas GK, Hennessy S, Brensinger CM, Acton EK, Bilker WB, Chung S, Dublin S, Horn JR, Manis MM, Miano TA, Oslin DW, Pham Nguyen TP, Soprano SE, Wiebe DJ, Leonard CE. Signals of Muscle Relaxant Drug Interactions Associated with Unintentional Traumatic Injury: A Population-Based Screening Study. CNS Drugs. 2022 Apr;36(4):389-400. [PMC free article: PMC9375100] [PubMed: 35249204]
28.Tayar J, Jabbour G, Saggi SJ. Severe hyperosmolar metabolic acidosis due to a large dose of intravenous lorazepam. N Engl J Med. 2002 Apr 18;346(16):1253-4. [PubMed: 11961161]
29.Podrizki A. Methocarbamol and myasthenia gravis. JAMA. 1968 Sep 23;205(13):938. [PubMed: 5695627]
30.Corcuff JB, Chardon L, El Hajji Ridah I, Brossaud J. Urinary sampling for 5HIAA and metanephrines determination: revisiting the recommendations. Endocr Connect. 2017 Aug;6(6):R87-R98. [PMC free article: PMC5527357] [PubMed: 28566493]
31.Lebby TI, Dugger K, Lipscomb JW, Leikin JB. Skeletal muscle relaxant ingestion. Vet Hum Toxicol. 1990 Apr;32(2):133-5. [PubMed: 2327059]
32.2023 ACMT Annual Scientific Meeting Abstracts – San Diego, CA. J Med Toxicol. 2023 Mar 23;19(2):63-168. [PMC free article: PMC10035466] [PubMed: 36952114]
33.Dillon C, Paulose-Ram R, Hirsch R, Gu Q. Skeletal muscle relaxant use in the United States: data from the Third National Health and Nutrition Examination Survey (NHANES III). Spine (Phila Pa 1976). 2004 Apr 15;29(8):892-6. [PubMed: 15082991]
34.GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1211-1259. [PMC free article: PMC5605509] [PubMed: 28919117]
35.Hartvigsen J, Hancock MJ, Kongsted A, Louw Q, Ferreira ML, Genevay S, Hoy D, Karppinen J, Pransky G, Sieper J, Smeets RJ, Underwood M., Lancet Low Back Pain Series Working Group. What low back pain is and why we need to pay attention. Lancet. 2018 Jun 09;391(10137):2356-2367. [PubMed: 29573870]
36.Foster NE, Anema JR, Cherkin D, Chou R, Cohen SP, Gross DP, Ferreira PH, Fritz JM, Koes BW, Peul W, Turner JA, Maher CG., Lancet Low Back Pain Series Working Group. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet. 2018 Jun 09;391(10137):2368-2383. [PubMed: 29573872]
37.Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004 Aug;28(2):140-75. [PubMed: 15276195]
38.Friedman BW, Cisewski D, Irizarry E, Davitt M, Solorzano C, Nassery A, Pearlman S, White D, Gallagher EJ. A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain. Ann Emerg Med. 2018 Mar;71(3):348-356.e5. [PMC free article: PMC5820149] [PubMed: 29089169]
39.Chen C, Hennessy S, Brensinger CM, Miano TA, Bilker WB, Dublin S, Chung SP, Horn JR, Tiwari A, Leonard CE. Comparative Risk of Injury with Concurrent Use of Opioids and Skeletal Muscle Relaxants. Clin Pharmacol Ther. 2024 Jul;116(1):117-127. [PMC free article: PMC11180590] [PubMed: 38482733]
(Disclosure sections from the original article are omitted as per instructions to only include title and content)
